Trial · NCT07235215
Vivatlac in Irritable Bowel Syndrome II (ViIBS2)
Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS pat
- Status
- Recruiting
- Sponsor
- The President Stanisław Wojciechowski State University of Applied Sciences in Kalisz
- Study type
- Interventional
- Phase
- No phase
- Enrollment
- 200 participants (planned)
- Start
- Nov 21, 2025
- Primary completion
- December 2026
- Conditions
- Irritable Bowel Syndrome
Summary
Multi-center,randomized, double-blind, placebo-controlled, 36 weeks trial investigating the effects of a nine-strain synbiotic (Vivatlac Synbiotikum) in IBS patients
Interventions
- Vivatlac Synbiotic Dietary supplement
- Placebo Dietary supplement
Locations
1 country: Poland.
| Facility | City | Country |
|---|---|---|
| District Hospital Jarocin | Jarocin | Poland |
| GP Clinic Spitalna | Jarocin | Poland |
| GP Clinic Wroclawska | Jarocin | Poland |
TreatIBS is an informational site and does not provide medical advice. The research summarized here may not apply to your situation. Talk with a clinician before starting, stopping, or changing any treatment.
Listing only. Eligibility is decided by the study team. TreatIBS is not involved in recruitment.